Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Type 1, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.41 (2.61%)
Data as of 05/26/17 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $15.32 with a 52 week high of $20.74 and a 52 week low of $13.06.
Recent NewsMore >>
Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
Audentes Therapeutics to Present At Upcoming Investor Conferences
Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Thomas Soloway
SVP and Chief Financial Officer
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.